Mouse anti-Human Tet2 Monoclonal Antibody | anti-Tet2 antibody

Tet2 antibody (mAb)(Clone 21F11)

Cat. Num. AAA388874

• Gene Names: TET2; MDS; KIAA1546
• Reactivity: Human
• Applications: Immunocytochemistry, Immunofluorescence, Immunoprecipitation, Western Blot
• Purity: Protein A Chromatography
• Synonyms: Tet2; Monoclonal Antibody; Tet2 antibody (mAb)(Clone 21F11); MDS; KIAA1546; anti-Tet2 antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgG1, k
• Clone Number: 21F11
• Purity/Purification: Protein A Chromatography
• Form/Format: Purified IgG in PBS with 30% glycerol and 0.035% sodium azide. Sodium azide is highly toxic.
• Concentration: 1ug/ul (varies by lot)

• Applicable Applications for anti-Tet2 antibody: Immunocytochemistry (ICC), Immunofluorescence (IF), Immunoprecipitation (IP), Western Blot (WB)
• Application Notes: Applications Validated:; IP: 1-2ul per IP; WB: 1-2ug/ml dilution
• Immunogen: This antibody was raised against a recombinant protein corresponding to amino acids 1-300 of human Tet2.
• Preparation and Storage: Some products may be shipped at room temperature. This will not affect their stability or performance. Avoid repeated freeze/thaw cycles by aliquoting items into single-use fractions for storage at -20 degree C for up to 2 years. Keep all reagents on ice when not in storage.1ug/ul

Immunoprecipitation (IP)

(Tes2 antibody (mAb) (Clone 21F11) tested by Immunoprecipitation. Tet2 detection by Immunoprecipitation. Lane 1: Input (25 ug of HL-60 whole cell lysate). Lane 2: Negative control mAb. Lane 3: Tet2 antibody at 1 ug/ml. 250 ug of HL-60 whole cell lysate per IP.)

Western Blot (WB)

(Tes2 antibody (mAb) (Clone 21F11) tested by Western blot. Tet2 detection by Western blot. Lane 1: HL-60 whole cell lysate (40 ug). Lane 2: Lymphoblastoid Tet2 negative (-/-) whole cell lysate (40 ug). Lane 3: Lymphoblastoid Tet2 positive (+/+) whole cell lysate (40 ug). All probed with Tet2 antibody at a 1 ug/ml dilution.)

Related Product Information for anti-Tet2 antibody

Short Description: Our Tet2 antibody (mAb)(Clone 21F11) was raised in a Mouse host. It has been validated for use in Immunocytochemistry, Immunofluorescence, Immunoprecipitation and Western blot; it has been shown to react with Human samples.

Background: Tet2 (tet methylcytosine dioxygenase 2) catalyzes the conversion of methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC). Plays an important role in myelopoiesis. The clear function of 5-hydroxymethylcytosine (hmC) is still unclear but it may influence chromatin structure and recruit specific factors or may constitute an intermediate component in cytosine demethylation and differentiation in the case of inflammation by regulating gene expression and macrophage differentiation.

Product Categories/Family for anti-Tet2 antibody

Primary Antibodies

NCBI and Uniprot Product Information

• NCBI GI #: 187761317
• NCBI GeneID: 54790
• NCBI Accession #: NP_001120680; AB_2736901
• NCBI GenBank Nucleotide #: NM_001127208.2
• UniProt Accession #: Q6N021; Q2TB88; Q3LIB8; Q96JX5; Q9HCM6; Q9NXW0; B5MDU0
• Molecular Weight: 133,481 Da
• NCBI Official Full Name: methylcytosine dioxygenase TET2 isoform a
• NCBI Official Synonym Full Names: tet methylcytosine dioxygenase 2
• NCBI Official Symbol: TET2
• NCBI Official Synonym Symbols: MDS; KIAA1546
• NCBI Protein Information: methylcytosine dioxygenase TET2; tet oncogene family member 2; probable methylcytosine dioxygenase TET2
• UniProt Protein Name: Methylcytosine dioxygenase TET2
• Protein Family: Tetraspanin
• UniProt Gene Name: TET2
• UniProt Synonym Gene Names: KIAA1546
• UniProt Entry Name: TET2_HUMAN

NCBI Description

The protein encoded by this gene is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. The encoded protein is involved in myelopoiesis, and defects in this gene have been associated with several myeloproliferative disorders. Two variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2011]

Uniprot Description

TET2: Catalyzes the conversion of methylcytosine (5mC) to 5- hydroxymethylcytosine (hmC). Plays an important role in myelopoiesis. The clear function of 5-hydroxymethylcytosine (hmC) is still unclear but it may influence chromatin structure and recruit specific factors or may constitute an intermediate component in cytosine demethylation. TET2 is frequently mutated in myeloproliferative disorders (MPD). These constitute a heterogeneous group of disorders, also known as myeloproliferative diseases or myeloproliferative neoplasms (MPN), characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. Included diseases are: essential thrombocythemia, polycythemia vera, primary myelofibrosis (chronic idiopathic myelofibrosis). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. Defects in TET2 are a cause of polycythemia vera (PV). A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly. TET2 is frequently mutated in systemic mastocytosis; also known as systemic mast cell disease. A condition with features in common with myeloproliferative diseases. It is a clonal disorder of the mast cell and its precursor cells. The clinical symptoms and signs of systemic mastocytosis are due to accumulation of clonally derived mast cells in different tissues, including bone marrow, skin, the gastrointestinal tract, the liver, and the spleen. Defects in TET2 are a cause of myelodysplastic syndrome (MDS). A heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS). Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. Myelodysplastic syndromes are considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. Belongs to the TET family. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: Tumor suppressor; EC 1.14.11.n2; Oxidoreductase

Chromosomal Location of Human Ortholog: 4q24

Molecular Function: protein binding; DNA binding; zinc ion binding; ferrous iron binding

Biological Process: spleen development; protein amino acid O-linked glycosylation; hemoglobin metabolic process; cell cycle; regulation of gene expression, epigenetic; post-embryonic development; myeloid progenitor cell differentiation; cytosine metabolic process; 5-methylcytosine catabolic process; gene expression; positive regulation of transcription from RNA polymerase II promoter; myeloid cell differentiation; kidney development

Disease: Myelodysplastic Syndrome